Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KPTI Karyopharm Therapeutics	$7.68 -1.7%	$4.69	$3.51 ▼ $16.95	$66.59M	0.28	127,487 shs	72,413 shs
NRXP NRx Pharmaceuticals	$2.52 -2.3%	$2.93	$1.10 ▼ $6.01	$49.92M	1.59	505,499 shs	291,024 shs
PRPH ProPhase Labs	$0.35 +5.4%	$0.37	$0.22 ▼ $3.00	$14.39M	-0.48	6.68 million shs	988,669 shs
VRCA Verrica Pharmaceuticals	$5.55 -1.9%	$6.59	$3.82 ▼ $25.20	$52.45M	1.92	43,056 shs	18,750 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KPTI Karyopharm Therapeutics	+4.69%	+20.15%	+78.72%	+72.41%	-34.92%
NRXP NRx Pharmaceuticals	-1.90%	-1.53%	-11.95%	-4.09%	+33.68%
PRPH ProPhase Labs	-4.17%	-0.27%	-25.92%	-9.89%	-86.03%
VRCA Verrica Pharmaceuticals	-5.19%	+1.80%	-16.64%	+3.87%	-76.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KPTI Karyopharm Therapeutics	3.9548 of 5 stars	3.4	0.0	4.6	2.9	2.5	0.6
NRXP NRx Pharmaceuticals	3.2286 of 5 stars	3.6	5.0	0.0	2.9	0.8	0.6
PRPH ProPhase Labs	1.2992 of 5 stars	0.0	5.0	0.0	3.4	0.0	0.6
VRCA Verrica Pharmaceuticals	4.6551 of 5 stars	3.1	5.0	4.7	3.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	342.71% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	1,030.95% Upside
PRPH ProPhase Labs	0.00	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	2.20	Hold	$80.00	1,341.44% Upside

Current Analyst Ratings Breakdown

Latest PRPH, KPTI, NRXP, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/19/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
8/11/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/4/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KPTI Karyopharm Therapeutics	$137.27M	0.49	N/A	N/A	($27.55) per share	-0.28
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.80) per share	N/A
PRPH ProPhase Labs	$6.77M	2.13	N/A	N/A	$0.28 per share	1.24
VRCA Verrica Pharmaceuticals	$7.57M	6.93	N/A	N/A	($1.85) per share	-3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.24	N/A	N/A	N/A	N/A	N/A	-550.94%	11/13/2025 (Estimated)
PRPH ProPhase Labs	-$53.36M	-$1.26	N/A	N/A	N/A	N/A	-262.42%	-76.48%	11/12/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$76.58M	-$8.28	N/A	N/A	N/A	N/A	N/A	-115.48%	11/3/2025 (Estimated)

Latest PRPH, KPTI, NRXP, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	-$0.98	-$0.67	-$0.98	N/A	N/A
8/13/2025	Q2 2025	PRPH ProPhase Labs	-$0.15	-$0.11	+$0.04	-$0.11	$3.55 million	$1.25 million
8/12/2025	Q2 2025	VRCA Verrica Pharmaceuticals	-$0.70	$0.02	+$0.72	$0.02	$4.37 million	$12.70 million
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRPH ProPhase Labs	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KPTI Karyopharm Therapeutics	N/A	0.99	0.94
NRXP NRx Pharmaceuticals	N/A	0.11	0.11
PRPH ProPhase Labs	0.20	0.96	0.93
VRCA Verrica Pharmaceuticals	N/A	1.26	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KPTI Karyopharm Therapeutics	66.44%
NRXP NRx Pharmaceuticals	4.27%
PRPH ProPhase Labs	9.45%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
KPTI Karyopharm Therapeutics	2.98%
NRXP NRx Pharmaceuticals	19.00%
PRPH ProPhase Labs	9.60%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable
NRXP NRx Pharmaceuticals	2	19.81 million	16.05 million	Optionable
PRPH ProPhase Labs	130	41.54 million	37.55 million	Optionable
VRCA Verrica Pharmaceuticals	40	9.45 million	4.35 million	Optionable

PRPH, KPTI, NRXP, and VRCA Headlines

Recent News About These Companies

101,125 Shares in Verrica Pharmaceuticals Inc. $VRCA Acquired by Kovitz Investment Group Partners LLC

August 26 at 3:50 AM | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Declines By 32.3%

August 22, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.3%

August 22, 2025 | americanbankingnews.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

August 14, 2025 | marketbeat.com

Verrica Posts Profit in Fiscal Q2

August 14, 2025 | theglobeandmail.com

Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 13, 2025 | finanznachrichten.de

Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Verrica Pharmaceuticals Regains Nasdaq Compliance

August 12, 2025 | msn.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

August 12, 2025 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025 | globenewswire.com

3VRCA : What to Expect from Verrica Pharmaceuticals's Earnings

August 11, 2025 | benzinga.com

Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 6, 2025 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from Brokerages

August 5, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?

August 3, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Rises By 1,164.0%

August 2, 2025 | marketbeat.com

Verrica Pharmaceuticals Implements Reverse Stock Split

August 1, 2025 | theglobeandmail.com

Verrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...

July 12, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com

July 11, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH, KPTI, NRXP, and VRCA Company Descriptions

Karyopharm Therapeutics NASDAQ:KPTI

$7.68 -0.13 (-1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.66 -0.01 (-0.20%)

As of 04:10 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

NRx Pharmaceuticals NASDAQ:NRXP

$2.52 -0.06 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 +0.05 (+1.98%)

As of 05:34 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

ProPhase Labs NASDAQ:PRPH

$0.35 +0.02 (+5.35%)

Closing price 04:00 PM Eastern

Extended Trading

$0.34 -0.01 (-1.59%)

As of 05:29 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Verrica Pharmaceuticals NASDAQ:VRCA

$5.55 -0.11 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$5.51 -0.04 (-0.72%)

As of 04:10 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time